Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · Real-Time Price · USD
46.44
+2.33 (5.28%)
At close: Aug 19, 2026, 4:00 PM EDT
47.95
+1.51 (3.25%)
After-hours: Aug 19, 2026, 7:48 PM EDT
Edgewise Therapeutics Employees
Edgewise Therapeutics had 127 employees as of June 30, 2026. The number of employees increased by 1 or 0.79% compared to the same quarter last year.
Employees
127
Change
1
Growth
0.79%
Revenue / Employee
n/a
Profits / Employee
-$1,552,929
Market Cap
5.04B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 127 | 1 | 0.79% |
| Mar 31, 2026 | 154 | 37 | 31.62% |
| Dec 31, 2025 | 146 | 36 | 32.73% |
| Sep 30, 2025 | 136 | 28 | 25.93% |
| Jun 30, 2025 | 126 | 29 | 29.90% |
| Mar 31, 2025 | 117 | 25 | 27.17% |
| Dec 31, 2024 | 110 | 22 | 25.00% |
| Sep 30, 2024 | 108 | 28 | 35.00% |
| Jun 30, 2024 | 97 | 23 | 31.08% |
| Mar 31, 2024 | 92 | 25 | 37.31% |
| Dec 31, 2023 | 88 | 29 | 49.15% |
| Sep 30, 2023 | 80 | 30 | 60.00% |
| Jun 30, 2023 | 74 | 32 | 76.19% |
| Mar 31, 2023 | 67 | 29 | 76.32% |
| Dec 31, 2022 | 59 | 28 | 90.32% |
| Sep 30, 2022 | 50 | 20 | 66.67% |
| Jun 30, 2022 | 42 | 16 | 61.54% |
| Mar 31, 2022 | 38 | 16 | 72.73% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Legend Biotech | 2,965 |
| Telix Pharmaceuticals | 1,184 |
| ACADIA Pharmaceuticals | 798 |
| CRISPR Therapeutics AG | 393 |
| Dyne Therapeutics | 289 |
| Relay Therapeutics | 202 |
| Celcuity | 155 |
| Parabilis Medicines | 145 |
EWTX News
- 8 days ago - Edgewise Therapeutics price target raised to $36 from $32 at Goldman Sachs - TheFly
- 13 days ago - Edgewise Therapeutics reports Q2 EPS (53c), consensus (47c) - TheFly
- 13 days ago - Edgewise Therapeutics Reports Second Quarter 2026 Financial Results - PRNewsWire
- 13 days ago - Edgewise Therapeutics Quarterly report: Q2 2026 - Filings
- 13 days ago - Edgewise Therapeutics Earnings release: Q2 2026 - Filings
- 4 weeks ago - Edgewise Therapeutics price target raised to $55 from $45 at Evercore ISI - TheFly
- 5 weeks ago - Edgewise Therapeutics completes sale of sevasemten for up to $2.65B - TheFly
- 5 weeks ago - Edgewise Therapeutics expects to initiate Phase 3 trial of EDG-7500 in Q4 - TheFly